Patricia Gallegos-Arreola Martha, Zúñiga González Guillermo Moisés, Figuera Luis Eduardo, Puebla Pérez Ana María, Delgado Saucedo Jorge Iván
División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, México.
J BUON. 2019 Nov-Dec;24(6):2369-2376.
Interleukin 10 (IL-10) gene polymorphisms are associated with different types of cancer, but these associations are inconsistent. The purpose of this study was to determine the frequency and association of the rs1800872 IL-10 gene polymorphism in Mexican women with breast cancer (BC).
The rs1800872 polymorphism was genotyped in 368 BC patients and 320 control women using the polymerase chain reaction (PCR).
The rs1800872 polymorphism was a risk factor for BC compared to controls and BC patients with genotypes CA (p=0.004) and AA, and in the recessive model (p=0.0002), dominant model (CA+AA; p=0.0001), and allele A ( p=0.0001). Additionally, differences were observed in BC patients with the CA and CAAA genotypes who had chemotherapy gastric and hematological toxicity (p=0.022) and tumor stage IV (p=0.013) as a risk factor. Genotypes were CA in breastfeeding (p=0.017), AA in gastric toxicity (p=0.048), and CAAA in tumor stage I-II (p=0.019) as protective risk factors. In BC carriers of: 1) CAAA genotype with tumor stage I-II and breast feeding (≥6 months), 2) CA genotype BC Luminal A with tumor stage I-II, 3) CA genotype BC Luminal B with breastfeeding (≥6 months), and 4) CAAA genotypes in BC HER2 with indices of cellular proliferation (Ki-67) that were elevated (≥20%), were considered to be protective factors in BC patients.
The IL-10 gene rs1800872 polymorphism was associated with BC susceptibility in this sample from the Mexican population.
白细胞介素10（IL-10）基因多态性与不同类型的癌症相关，但这些关联并不一致。本研究的目的是确定墨西哥乳腺癌（BC）女性中rs1800872 IL-10基因多态性的频率及相关性。
采用聚合酶链反应（PCR）对368例BC患者和320例对照女性进行rs1800872多态性基因分型。
与对照组及基因型为CA（p=0.004）和AA的BC患者相比，rs1800872多态性是BC的一个危险因素，在隐性模型（p=0.0002）、显性模型（CA+AA；p=0.0001）和等位基因A（p=0.0001）中均如此。此外，在接受化疗出现胃和血液学毒性（p=0.022）以及肿瘤分期为IV期（p=0.013）作为危险因素的CA和CAAA基因型的BC患者中观察到差异。基因型为CA与母乳喂养相关（p=0.017），AA与胃毒性相关（p=0.048），CAAA与肿瘤分期I-II期相关（p=0.019），这些均为保护性危险因素。在BC携带者中：1）肿瘤分期为I-II期且母乳喂养（≥6个月）的CAAA基因型；2）肿瘤分期为I-II期的CA基因型BC Luminal A；3）母乳喂养（≥6个月）的CA基因型BC Luminal B；4）细胞增殖指数（Ki-67）升高（≥20%）的BC HER2中的CAAA基因型，被认为是BC患者的保护因素。
在来自墨西哥人群的该样本中，IL-10基因rs1800872多态性与BC易感性相关。
